Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors - Le Tourneau, C. (Paris-Saclay University) ; Becker, H. (University of Freiburg) ; Claus, R. (Medical Faculty Augsburg University) ; Elez, Elena (Vall d'Hebron Institut d'Oncologia) ; Ricci, F. (Paris-Saclay University) ; Fritsch, R. (University of Freiburg) ; Silber, Y. (Medical Faculty Augsburg University) ; Hennequin, A. (Centre Georges-François Leclerc) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Jayadeva, G. (Boehringer Ingelheim International GmbH) ; Luedtke, D. (Boehringer Ingelheim Pharma GmbH and Co KG) ; He, M. (Boehringer Ingelheim Pharmaceuticals Inc.) ; Isambert, N. (Centre Georges-François Leclerc) ; Universitat Autònoma de Barcelona
 
Comments (0) | Reviews (0)
Start a discussion about any aspect of this document.

 Subscribe to this discussion. You will then receive all new comments by email.

Add comment


Once logged in, authorized users can also attach files.
Note: you have not defined your nickname.
N/D will be displayed as the author of this comment.
          You can use some HTML tags: <a href>, <strong>, <blockquote>, <br />, <p>, <em>, <ul>, <li>, <b>, <i>